{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:50:44Z","timestamp":1770475844001,"version":"3.49.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,11,13]],"date-time":"2002-11-13T00:00:00Z","timestamp":1037145600000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Tumour lysis syndrome (TLS) is caused by rapid breakdown of malignant cells resulting in electrolyte disturbances and acute renal failure. TLS has rarely been described in patients with acute myelogenous leukaemia (AML). Between November 1997 and July 2001, 114 consecutive adult AML patients aged\u2003&lt;60\u2003yr received induction chemotherapy consisting of cytosine arabinoside 1.5\u2003g\u2003m<jats:sup>\u22122<\/jats:sup> q\u200312\u2003h\u2003\u00d7\u200312 doses and daunorubicin 45\u2003mg\u2003m<jats:sup>\u22122<\/jats:sup>\u2003d<jats:sup>\u22121<\/jats:sup>\u2003\u00d7\u20033\u2003doses. During induction chemotherapy (CT), seven patients (6.1%, 95% CI 2.5\u201312.2) developed fulminant TLS, resulting in acute renal failure; five of these seven patients had inversion of chromosome 16 [inv(16)(p13;q22)], and one patient had a biological equivalent [t(16,16)(p13;q22)]. Four of the TLS patients underwent leukapheresis for a presenting white blood cell (WBC) count &gt;\u200a100\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\u2003L<jats:sup>\u22121<\/jats:sup> prior to commencing chemotherapy, and six patients subsequently required haemodialysis for a median of 2 (range 1\u20138) wk. One TLS patient died of intracerebral hemorrhage on day 10 and another patient of multiorgan failure on day 17. Of the other five patients, all entered a complete remission (CR) and recovered normal renal function. Four patients remain in continuous CR [median follow\u2010up 20 (range 12\u201325) months]. One patient relapsed at 12\u2003months and again developed TLS on re\u2010induction. In univariate analysis, TLS patients were more likely to have an elevated presentation and pre\u2010chemotherapy WBC counts, elevated serum creatinine, and uric acid levels at presentation, as well as an inv(16). In multivariate analysis, only serum creatinine and inv(16) remained statistically significant (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001 for each). Patients with an inv(16) are a unique AML subgroup at high risk for fulminant TLS.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2002.02802.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:53:29Z","timestamp":1047408809000},"page":"193-199","source":"Crossref","is-referenced-by-count":11,"title":["Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22)"],"prefix":"10.1034","volume":"69","author":[{"given":"M.D.","family":"Seftel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bruyere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Copland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.E.","family":"Hogge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.E.","family":"Horsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.H.","family":"Nantel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.D.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.L.","family":"Toze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.J.","family":"Nevill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,11,13]]},"reference":[{"key":"e_1_2_17_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90254-4"},{"key":"e_1_2_17_3_2","first-page":"322","article-title":"Metabolic emergencies in the cancer patient","volume":"27","author":"Flombaum CD","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_17_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840601)53:11<2425::AID-CNCR2820531111>3.0.CO;2-R"},{"key":"e_1_2_17_5_2","first-page":"75","article-title":"Renal and metabolic toxicities of cancer chemotherapy","volume":"9","author":"Schilsky RL","year":"1982","journal-title":"Semin Oncol"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199902)32:2<156::AID-MPO20>3.0.CO;2-N"},{"key":"e_1_2_17_7_2","first-page":"273","article-title":"Tumor lysis syndrome","volume":"13","author":"Arrambide K","year":"1993","journal-title":"Semin Nephrol"},{"key":"e_1_2_17_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90286-7"},{"key":"e_1_2_17_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197008132830708"},{"key":"e_1_2_17_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204328"},{"key":"e_1_2_17_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830350106"},{"key":"e_1_2_17_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2998"},{"key":"e_1_2_17_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1991.tb00133.x"},{"key":"e_1_2_17_14_2","volume-title":"Applied Logistic Regression","author":"Hosmer DW","year":"1989"},{"key":"e_1_2_17_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2000.0114"},{"key":"e_1_2_17_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198309153091103"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<368::AID-CNCR14>3.0.CO;2-X"},{"key":"e_1_2_17_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402029"},{"key":"e_1_2_17_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02866.x"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402"},{"key":"e_1_2_17_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_17_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.5.1710.1710"},{"key":"e_1_2_17_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841"},{"key":"e_1_2_17_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401839"},{"key":"e_1_2_17_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800100304"},{"key":"e_1_2_17_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200201000-00015"},{"key":"e_1_2_17_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008304401661"},{"key":"e_1_2_17_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.3.776"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.3043.3043"},{"key":"e_1_2_17_30_2","first-page":"109a","article-title":"Quantitative immunophenotype (QUIP) pattern of CD34high, CD13high and CD33low identifies patients with acute myelogenous leukemia (AML) with inv(16)","volume":"98","author":"Khoury H","year":"2001","journal-title":"Blood"},{"key":"e_1_2_17_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402142"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.02802.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2002.02802.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T03:36:52Z","timestamp":1692675412000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2002.02802.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1034\/j.1600-0609.2002.02802.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2002.02802.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}